{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-108082","form_type":"8-K","ticker":"AARD","cik":"0001774857","company_name":"Aardvark Therapeutics, Inc.","filed_at":"2025-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.949113+00:00","generated_at":"2026-05-17T13:58:10.568401+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Aardvark Therapeutics Q2 net loss $14.4M; advances ARD-201 obesity trials and expands PWS trial to younger patients","bullets":["Net loss of $14.4M in Q2 2025 vs $5.4M in Q2 2024; R&D expenses rose to $13.1M.","Cash, cash equivalents, and short-term investments of $141.8M as of June 30, 2025; funds operations into 2027.","Preclinical data shows ARD-201 prevents weight regain after GLP-1RA discontinuation; Phase 2 POWER trial in H2 2025, STRENGTH in H1 2026.","Phase 3 HERO trial for ARD-101 in PWS to expand to patients under 13; topline data expected Q3 2026.","Appointed new CSO, CCO, SVP Regulatory, and General Counsel in May 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-108082","json":"https://secwatch.observer/filing/0000950170-25-108082.json","markdown":"https://secwatch.observer/filing/0000950170-25-108082.md","text":"https://secwatch.observer/filing/0000950170-25-108082.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1774857/000095017025108082/0000950170-25-108082-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1774857/000095017025108082/ck0001774857-20250813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:58:10.568401+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}